Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052

Philip J. Palumbo, Ethan A. Wilson, Estelle Piwowar-Manning, Marybeth McCauley, Theresa Gamble, Newton Kumwenda, Joseph Makhema, Nagalingeswaran Kumarasamy, Suwat Chariyalertsak, James G. Hakim, Mina C. Hosseinipour, Marineide G. Melo, Sheela V. Godbole, Jose H. Pilotto, Beatriz Grinsztejn, Ravindre Panchia, Ying Q. Chen, Myron S. Cohen, Susan Eshleman, Jessica Marie Louise Fogel

Research output: Contribution to journalArticle

Abstract

Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: Time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: Higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.

Original languageEnglish (US)
Article numbere0177281
JournalPLoS One
Volume12
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

melting
pretreatment
Association reactions
HIV
drug resistance
HIV infections
assays
Assays
Melting
demographic statistics
cells
genomics
Treatment Failure
genome
Therapeutics
Genes
Freezing
Pharmaceutical Preparations
CD4 Lymphocyte Count
Drug Resistance

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Palumbo, P. J., Wilson, E. A., Piwowar-Manning, E., McCauley, M., Gamble, T., Kumwenda, N., ... Fogel, J. M. L. (2017). Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One, 12(5), [e0177281]. https://doi.org/10.1371/journal.pone.0177281

Association of HIV diversity and virologic outcomes in early antiretroviral treatment : HPTN 052. / Palumbo, Philip J.; Wilson, Ethan A.; Piwowar-Manning, Estelle; McCauley, Marybeth; Gamble, Theresa; Kumwenda, Newton; Makhema, Joseph; Kumarasamy, Nagalingeswaran; Chariyalertsak, Suwat; Hakim, James G.; Hosseinipour, Mina C.; Melo, Marineide G.; Godbole, Sheela V.; Pilotto, Jose H.; Grinsztejn, Beatriz; Panchia, Ravindre; Chen, Ying Q.; Cohen, Myron S.; Eshleman, Susan; Fogel, Jessica Marie Louise.

In: PLoS One, Vol. 12, No. 5, e0177281, 01.05.2017.

Research output: Contribution to journalArticle

Palumbo, PJ, Wilson, EA, Piwowar-Manning, E, McCauley, M, Gamble, T, Kumwenda, N, Makhema, J, Kumarasamy, N, Chariyalertsak, S, Hakim, JG, Hosseinipour, MC, Melo, MG, Godbole, SV, Pilotto, JH, Grinsztejn, B, Panchia, R, Chen, YQ, Cohen, MS, Eshleman, S & Fogel, JML 2017, 'Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052', PLoS One, vol. 12, no. 5, e0177281. https://doi.org/10.1371/journal.pone.0177281
Palumbo PJ, Wilson EA, Piwowar-Manning E, McCauley M, Gamble T, Kumwenda N et al. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One. 2017 May 1;12(5). e0177281. https://doi.org/10.1371/journal.pone.0177281
Palumbo, Philip J. ; Wilson, Ethan A. ; Piwowar-Manning, Estelle ; McCauley, Marybeth ; Gamble, Theresa ; Kumwenda, Newton ; Makhema, Joseph ; Kumarasamy, Nagalingeswaran ; Chariyalertsak, Suwat ; Hakim, James G. ; Hosseinipour, Mina C. ; Melo, Marineide G. ; Godbole, Sheela V. ; Pilotto, Jose H. ; Grinsztejn, Beatriz ; Panchia, Ravindre ; Chen, Ying Q. ; Cohen, Myron S. ; Eshleman, Susan ; Fogel, Jessica Marie Louise. / Association of HIV diversity and virologic outcomes in early antiretroviral treatment : HPTN 052. In: PLoS One. 2017 ; Vol. 12, No. 5.
@article{f17e1df119c042c3adce7d80a934fcdc,
title = "Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052",
abstract = "Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: Time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: Higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.",
author = "Palumbo, {Philip J.} and Wilson, {Ethan A.} and Estelle Piwowar-Manning and Marybeth McCauley and Theresa Gamble and Newton Kumwenda and Joseph Makhema and Nagalingeswaran Kumarasamy and Suwat Chariyalertsak and Hakim, {James G.} and Hosseinipour, {Mina C.} and Melo, {Marineide G.} and Godbole, {Sheela V.} and Pilotto, {Jose H.} and Beatriz Grinsztejn and Ravindre Panchia and Chen, {Ying Q.} and Cohen, {Myron S.} and Susan Eshleman and Fogel, {Jessica Marie Louise}",
year = "2017",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0177281",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Association of HIV diversity and virologic outcomes in early antiretroviral treatment

T2 - HPTN 052

AU - Palumbo, Philip J.

AU - Wilson, Ethan A.

AU - Piwowar-Manning, Estelle

AU - McCauley, Marybeth

AU - Gamble, Theresa

AU - Kumwenda, Newton

AU - Makhema, Joseph

AU - Kumarasamy, Nagalingeswaran

AU - Chariyalertsak, Suwat

AU - Hakim, James G.

AU - Hosseinipour, Mina C.

AU - Melo, Marineide G.

AU - Godbole, Sheela V.

AU - Pilotto, Jose H.

AU - Grinsztejn, Beatriz

AU - Panchia, Ravindre

AU - Chen, Ying Q.

AU - Cohen, Myron S.

AU - Eshleman, Susan

AU - Fogel, Jessica Marie Louise

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: Time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: Higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.

AB - Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm3. A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: Time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: Higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=85019034575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019034575&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0177281

DO - 10.1371/journal.pone.0177281

M3 - Article

C2 - 28481902

AN - SCOPUS:85019034575

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0177281

ER -